Onram company

Alnylam is a biopharmaceutical company that develops new therapies based on RNA interference or RNAi. The company is applying its treatment expertise to RNAi to meet the main medical needs, but many of these needs cannot be met by the main drug categories at present: small molecules or antibody drugs. Alnylam is taking the lead in transforming RNAi into a new class of innovative drugs, and its peer-reviewed research results have been published in world-class scientific journals including Nature, Natural Medicine and Cell. The company is using these capabilities to establish a wide range of RNAi treatment channels; Its most important plan is the second phase of human clinical trial for the treatment of respiratory syncytial virus (RSV) infection in cooperation with Cubist and Kyowa Hakko. In addition, the company is developing RNAi therapy to treat a variety of diseases, including liver cancer, hypercholesterolemia, Huntington's disease and TTR amyloidosis. The company holds a leading position in basic patents, technologies and expertise of RNAi, which enables it to form major alliances with leading companies such as Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin and Cubist. In order to reflect the company's views on major scientific, clinical and commercial initiatives, Alnylam established "RNAi 20 10" in June 2008, which includes the following plans of the company: significantly expanding the scope of RNAi treatment delivery solutions, having four or more clinical development plans and establishing four or more new business partnerships, all of which are on 2010. Alnylam and Isis*** both own Regulus Therapeutics Inc, which focuses on the discovery, development and commercialization of MicroRNA therapy. Alnylam was founded in 2002 and is headquartered in Cambridge, Massachusetts.